Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 4 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 12215138

    Compositions and methods for internalizing enzymes

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  2. US 12215131

    IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  3. US 12215322

    Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  4. US 12214023

    Compositions and methods for expressing factor IX

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  5. US 12209180

    Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  6. US 12209238

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  7. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  8. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  9. US 12186378

    Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  10. US 12187772

    IL10 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  11. US 12187792

    IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  12. US 12180272

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  13. US 12168036

    Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  14. US 12169199

    Activity based host cell protein profiling

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  15. US 12168681

    Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  16. US 12163192

    Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  17. US 12162943

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  18. US 12161097

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  19. US 12157758

    Readily isolated bispecific antibodies with native immunoglobulin format

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  20. US 12157891

    Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  21. US 12152067

    Human antibodies to ebola virus glycoprotein

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  22. US 12150959

    Chimeric antigen receptors with BCMA specificity and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  23. US 12144864

    Tubulysins and protein-tubulysin conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  24. US 12139546

    Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted